Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
about
Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particlesPharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in TanzaniaIntensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.Mortality in HIV-infected patients with tuberculosis treated with streptomycin and a two-week intensified regimen: data from an HIV cohort study using inverse probability of treatment weightingPharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.Mortality among patients with tuberculosis requiring intensive care: a retrospective cohort study.Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.Extensively drug-resistant tuberculosis: a new face to an old pathogen.Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.Therapeutic drug monitoring in the treatment of active tuberculosisLow Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIVUrine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept studySerum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorptionA simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.HIV infection and multidrug-resistant tuberculosis: the perfect storm.Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa.Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research.Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.Adequacy of Rifampin Absorption after Jejunostomy Tube Administration.Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV CoinfectionMathematical models of the epidemiology and control of drug-resistant TB.Severe tuberculosis requiring ICU admission.Tuberculous meningitis in adults: a review of a decade of developments focusing on prognostic factors for outcome.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults.New drugs for tuberculosis.Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis.Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.The challenges of pharmacokinetic variability of first-line anti-TB drugs.Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma.Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography/tandem mass spectrometry.
P2860
Q28396917-53BB0F67-63EF-4C95-B216-3D62695F7D51Q28550488-093A6A21-85BF-45FA-BF16-00CE9DA93067Q30498213-9FA62255-F61C-43A8-A256-E7BB4F9BEDD4Q31102969-619A5625-8455-4D12-A7D4-0BA62D8350B0Q33282527-25A33580-BECE-4D2D-B077-BEFBEEDAD6CBQ33433684-D2D85879-319B-483D-B6C4-37DD7DCF8FA4Q33537492-E33EF5F7-F1EC-483E-8537-1ADC2BB5E0A7Q33843657-5C76374E-2DB9-41F7-A040-762208F6D2E8Q34150929-B38A6087-1616-41D6-8926-69AE96E638E0Q34453677-35048504-4805-40D8-87CF-CD8AFC497B0BQ34510679-5BFD9072-9FE9-44F4-8678-76BA12807B8DQ34561741-D2B8844B-4AF7-43E5-AE06-D40B97A77FFAQ35191432-3F5B0BD7-2444-4AAE-A709-DEE42CECDCC2Q35487794-CB211814-2AE8-44B8-9E87-4A307D0E6581Q35778303-33008BD5-7EC2-4D8C-B57A-C5AA90244194Q35941434-335735C8-797C-4F87-A035-DD16AF715FB1Q36036963-FFFB326E-99F3-46BF-8790-B04080DB21A3Q36439129-2A4CB1DC-612E-497D-B760-D1B59DC99A96Q36702972-E14EAC2D-E1AA-4438-9DF5-46AB13D71485Q36706812-B7C60D05-FE12-433E-95C8-9B30127F548CQ36877246-A624F8D3-F198-4B13-8429-00CE92242624Q36969720-970F5848-5438-409E-A81E-32E5CC1AF402Q37053021-8F4E03CE-5BAF-4A30-813D-29362B8117E3Q37143499-D3DFC314-3F09-49E6-8A6C-1C610170021DQ37145913-FBD0F9A1-3E86-4E54-820B-36DBA320F6BAQ37287701-28189C7A-BB13-4B7D-816C-C23B4073E748Q37352344-C972C0C4-6008-4972-BB36-01F903705706Q37613004-8CF308FD-AE7C-4DC7-B0E3-2D4EA46D12E2Q37754966-0EEF36ED-A018-4F44-9AEB-71974369C4D7Q38025340-516A0591-561C-45FD-9A70-39F31AFE94C4Q38041192-EF92BC40-0F98-47BD-A9A9-B5E152C25170Q38213320-2CB4B3EB-2F7E-4454-A7BA-BE65F233EB2BQ38244769-75950D7D-0547-4A10-89B3-4907E1103EECQ38246281-8B141E81-A4BC-466A-A813-31402BD6EADDQ38852090-4534336D-CFAB-4C2C-8157-A695D76A3424Q38857648-5F7C9C6B-C997-42F8-9862-845C38BF4398Q38865905-B79BBC51-F913-4A7C-8875-8862AE3A336FQ38977166-4F6C0F46-CD96-437C-A1F5-88A47AF0F1C2Q39630732-4FD6D733-9E48-470E-A8F8-715D2AF8BF3FQ40568451-ABCEA267-0821-4E9A-8F83-5ACE76CC0C94
P2860
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Serum concentrations of antimy ...... nary tuberculosis in Botswana.
@en
type
label
Serum concentrations of antimy ...... nary tuberculosis in Botswana.
@en
prefLabel
Serum concentrations of antimy ...... nary tuberculosis in Botswana.
@en
P2093
P2860
P356
P1476
Serum concentrations of antimy ...... nary tuberculosis in Botswana.
@en
P2093
Aderonke Oyewo
Arthur L Reingold
Charles A Peloquin
Elizabeth A Talbot
Howard J Moffat
Philip Hopewell
Themba L Moeti
Thomas A Kenyon
Tracy B Agerton
Williamson Z Bradford
P2860
P304
P356
10.1086/431984
P407
P577
2005-07-08T00:00:00Z